Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 Apr 20;36(12)
认识到ALK+ NSCLC不是一个单一的疾病实体,而是由不同的ALK融合变异体组成,这些融合变异体具有不同的潜在基因组改变,特别是调节治疗反应的TP53突变,这为进一步优化ALK+ NSCLC患者的治疗提供了证据,这些治疗可能导致改善生存。 关键词:EML4...
The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ ...
参考文献 Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Published at jco.org on January 26, 2018. 责任编辑:肿瘤资讯-宋小编 28个肿瘤相关临床试验招募患者 点击下方图片即可查看详情
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations (Journal of Thoracic Oncology, IF: 20.4) Alessandra Bearz, Jean-François Martini, Jacek Jassem, Sang-We Kim...
[0007] 据文献报道,目前只有3株肺癌细胞系拥有EML4-ALK融合基因表达,分别是H2228 (EML4-ALK variant3a/b),H3122(EML4-ALK variant I),DFC1032(EML4-ALK variant l)〇 其中ATCC细胞库中有收录H2228细胞系,但截至目前为止在ATCC中关于H2228细胞系的资料 记载中并没有显示其有EML4-ALK的融合基因突变,另外两株...
[0021] 本发明进一步提出了一种焦磷酸测序法检测EML4-ALK融合基因的试剂盒,所述 的EML4-ALK为EML4-ALK variant 1和EML4-ALK variant 3中的任意一种或两种,其特征 在于,所述试剂盒包含质控品和如下引物:[0022] (1)对于 EML4-ALK variant 1 基因,[0023] 扩增引物为:[0024] 上游引物:5,-CACACCTGGGAAAGG...
ALK融合基因.EML4拼接EML4-ALK variant 1外 显子13 variant 3a/b-/-/ins69/-/-/-/EML4-ALK variant 3a/b 外显子6 variant 1-/-/ins33/-/EML4-ALK variant 2外显子20 variant 2-/-/ins18/-与ALK拼接外显子20的融合类型有23 例;EML4拼接EML4-ALK variant 5a/b外显子2-/ins117外显 子17 ins...
EML4-ALKvariant518 EML4-ALKvariant5a/b2 -20488 -/ins11720 【检测原理】 本试剂盒由特异性引物、探针、PCR缓冲液、Taq酶、核苷酸单体(dNTPs)等成分组成,样品RNA经逆转录获得cDNA,然后利用特异引物对基因序列进行高精准PCR扩增放大,与此同时,利用探针对扩增产物结合并被仪器检测,结合特别的PCR反应程序和高特异Taq酶...
All 7 double positive cases were EML4-ALK variant 1 (VI), EGFR 19 exons deletion mutation (19-del) in 3 cases (42.9 %). EGFR L858R mutations in 2 cases (28.5 %), and L861Q G719X mutation of each 1 case (14.3 %). In 7 cases of double positive mutation...